OraMelts Drug Delivery Platform: Opportunity for Leadership in IntraOral Drug Delivery

The Sage Group is representing Quest Consumer Health Holdings, the owner of the OraMelts manufacturing facility and patent portfolio, in their search for one or more partners with which it can collaborate to expand the applications of its unique and highly successful OraMelts oral adhesive disc drug delivery technology. Proprietary products using this technology are already sold in major US pharmacy chains in Europe and Australia.

The partnership may include an exclusive worldwide license to the OraMelts patents and know-how in the prescription pharmaceutical field and/or for a specific therapeutic focus.

The OraMelts technology offers convenient, sustained, hours-long delivery of drugs into the bloodstream via the buccal membrane in the oral cavity overnight and/or during the day avoiding first pass metabolic effects seen with orally delivered pills, capsules, and caplets. Quest holds IP and knowhow for variations of release time by use of a range of excipients.

Buccal administration can provide better bioavailability of some drugs and a more rapid onset of action compared to oral administration because the medication does not pass through the digestive system and thereby avoids first pass metabolism. Buccal drugs can:

· Get into the systemic circulation quickly

· Be used with patients who have trouble swallowing medication

· Be used when medication doesn’t absorb very well in the stomach

· Avoid drug action being decreased by digestion

· Deliver drugs while patients sleep

OraMelts adhering discs can also be used to time release ingredients into saliva such as fungicides, anti-inflammatories, antibiotics, antivirals, or anti-cancer drugs to treat epithelium in the mouth or throat.

The Company has existing non-prescription products in market for dry mouth, mouth sores and other related syndr